Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.

To assess the cost-effectiveness of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China. A cost-consequence analysis (CCA) was conducted, considering both healthcare system and patient out-of-pocket perspectives. We considered the costs of medications, diagnostics and hospitalization and the consequences of mortality, response rate and adverse events. From the healthcare system perspective, compared with voriconazole, isavuconazole saved 967.39 Chinese Yuan (CNY) and posaconazole saved 8624.82 CNY. From the patient out-of-pocket perspective, compared with voriconazole, isavuconazole saved 1056.00 CNY, posaconazole increased 3153.83 CNY. The CCA demonstrated that isavuconazole exhibited higher medical costs but lower out-of-pocket costs compared with posaconazole, while there were no significant differences in consequences. Isavuconazole is potentially the most economical option.